UK regulators balk at price of Alexion's Soliris

|About: Alexion Pharmaceutical... (ALXN)|By:, SA News Editor

Alexion Pharmaceuticals (ALXN) waits for approval to sell its blockbuster drug Soliris in the UK.

The National Institute for Health and Clinical Excellence (NICE) wants to examine the company's R&D costs for the drug to help it determine the appropriate reimbursement, considering its high cost.

Soliris is the most expensive drug in the world. Annual treatment cost runs £340,000 (US$569,000).

NICE's evaluation of the cost/benefits of the product falls under its new "ultra orphan" disease treatment review process. For Soliris, it has taken three years with no end in sight.

There are ~170 patients in the UK that would be eligible for Soliris, representing a cost to the National Health Service of 58M Pounds ($97M).

Soliris sales were $1.6B last year, with a forecast of $3.4B by 2018.